Low back pain market growth driven by increased instances of the disease

KOLKATA, India - May 18, 2015 - PRLog -- Low back pain is commonly known as lumbago. This is one of the commonest diseases to afflict people from all over the world. According to research carried out in different countries, almost 40% of the global population suffers from lumbago at some point in their life. Low back pain can be classified into mainly three categories according to the duration for which it lasts- acute which last for less than 6 weeks, sub-chronic which lasts for between 6 and 12 weeks, and chronic which lasts more than 12 weeks. In the United States alone, 3 million people are suffering from low back pain currently. The USA market will reach a value of USD 23 billion by the year 2018.

This report, Low Back Pain - Pipeline Review, H2 2014, provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Low Back Pain and special features on late-stage and discontinued projects. It features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. There is a review of the Low Back Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

Current trends in the market

There have been several developments in the low back pain pipeline in recent times. Some of the major pharmaceutical companies have moved onto the next stage of product development. Collegium Pharmaceutical Inc. has released their new product, Oxycodone DETERx, an opioid formulation, listing its advantages over alternatives. Mesoblast Limited, a regenerative medicine company, has completed its Phase 2 trial of allogeneic, Mesenchymal Precursor Cells (MPCs) injected into damaged intervertebral discs. The trial has completed six-month follow-up for all 100 patients enrolled. Purdue Pharma L.P., another leading player in the market, announced Positive Phase 3 Clinical Trial Results of its Once-Daily Hydrocodone Bitartrate Extended-Release Tablets.

For further insights, click here